Division of Neonatology, Department of Pediatrics, Southern Illinois University School of Medicine, St. John's Children's Hospital, Springfield, Illinois 62794-9676, USA.
Am J Perinatol. 2013 Apr;30(4):297-301. doi: 10.1055/s-0032-1324697. Epub 2012 Aug 14.
To investigate the impact of in utero selective serotonin reuptake inhibitor (SSRI) exposure on neurodevelopment in a cohort of preterm infants.
Retrospective case control study of preterm infants ≤36(6/7) weeks gestation with in utero SSRI exposure. Subjects were matched to controls by gestational age, year of birth, birth weight, gender, and age at neurodevelopmental assessment. Neurodevelopment was assessed with the Bayley Infant Neurodevelopmental Screener and the Bayley Scales of Infant Development.
The 19 infants with in utero SSRI exposure were similar to controls in demographic data, birth weight, and in-hospital morbidity. The mean ± standard deviation (SD) Mental Developmental Index score for study infants at 36 months was 94 ± 15 versus 91 ± 10 for controls (p = 0.46). The mean ± SD Psychomotor Developmental Index score was also similar between groups: 79 ± 21 for study infants versus 75 ± 20 for control infants (p = 0.72). Other neurodevelopmental outcomes were comparable.
In this cohort of preterm infants, in utero SSRI exposure was not associated with adverse neurodevelopment above the baseline risk for this degree of prematurity. Larger studies are needed to obviate the risk of a type II error.
研究在早产儿队列中，胎儿选择性 5-羟色胺再摄取抑制剂（SSRI）暴露对神经发育的影响。
对≤36(6/7) 周龄有胎儿 SSRI 暴露的早产儿进行回顾性病例对照研究。通过胎龄、出生年份、出生体重、性别和神经发育评估时的年龄对受试者进行匹配对照。采用贝利婴幼儿神经发育筛查量表和贝利婴幼儿发育量表评估神经发育。
19 名胎儿 SSRI 暴露的婴儿在人口统计学数据、出生体重和院内发病率方面与对照组相似。研究组婴儿在 36 个月时的平均（±标准差[SD]）精神发育指数评分与对照组相比为 94 ± 15 对 91 ± 10（p = 0.46）。两组间精神运动发育指数的平均（±SD）评分也相似：研究组婴儿为 79 ± 21，对照组婴儿为 75 ± 20（p = 0.72）。其他神经发育结果也相似。
在本早产婴儿队列中，与该程度早产儿的基线风险相比，胎儿 SSRI 暴露与不良神经发育无关。需要更大的研究来避免第二类错误的风险。
